https://www.pharmaradar360.com/article/molecular-cancer-therapeutics-improving-immune-checkpoint-blockade-efficacy-in-m-e4eb0f79e79b2424Pharma Surgeen2026-07-02T16:23:19.000ZMolecular Cancer Therapeutics: Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertibhttps://www.pharmaradar360.com/article/veraxa-biotech-collaborates-with-atum-on-cell-line-development-to-advance-lead-b-d66d0fbf266be21fPharma Surgeen2026-07-02T16:18:27.000ZVERAXA Biotech Collaborates with ATUM on Cell Line Development to Advance Lead BiTAC®-TCE Programhttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-reopening-of-the-review-period-c13fb2a6ff8211a5Pharma Surgeen2026-07-02T16:13:28.000ZOn behalf of Respighi BidCo S.p.A – Reopening of the review periodhttps://www.pharmaradar360.com/article/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-24938326737a03ddPharma Surgeen2026-07-02T16:09:49.000ZTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026https://www.pharmaradar360.com/article/nhs-injury-costs-recovery-scheme-april-2026-to-march-2027-8ea107a36a0e2402Pharma Surgeen2026-07-02T16:01:03.000ZNHS injury costs recovery scheme: April 2026 to March 2027https://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-e18dc448dade6b1fPharma Surgeen2026-07-02T15:58:54.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/nearly-1-million-bottles-of-a-heart-failure-drug-were-just-recalled-check-your-m-3d53f997331a7c60Pharma Surgeen2026-07-02T15:00:11.000ZNearly 1 Million Bottles of a Heart Failure Drug Were Just Recalled — Check Your Medicine Cabinethttps://www.pharmaradar360.com/article/work-related-quality-of-life-of-the-adult-social-care-workforce-in-england-in-20-5dda61eaa33e2f01Pharma Surgeen2026-07-02T15:00:01.000ZWork-related quality of life of the adult social care workforce in England in 2025https://www.pharmaradar360.com/article/biotech-s-china-problem-an-issue-of-national-security-or-economic-value-for-the-28a1f5fb9a7d2451Pharma Surgeen2026-07-02T14:58:43.000ZBiotech’s China problem: An issue of national security or economic value for the US?https://www.pharmaradar360.com/article/how-pitt-s-bioforge-kept-a-new-york-based-biotech-startup-s-presence-in-pittsbur-630b2601c518d62bPharma Surgeen2026-07-02T14:56:04.000ZHow Pitt’s BioForge kept a New York-based biotech startup’s presence in Pittsburghhttps://www.pharmaradar360.com/article/guidance-medicines-that-you-cannot-export-from-the-uk-or-hoard-4663215c934b740cPharma Surgeen2026-07-02T14:46:34.000ZGuidance: Medicines that you cannot export from the UK or hoardhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-surges-13-with-a-9-day-winning-spree-f3207c4d07050271Pharma Surgeen2026-07-02T14:43:01.000ZWest Pharmaceutical Services Stock Surges 13%, With A 9-Day Winning Spreehttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-02T14:30:05.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-02T14:30:05.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/ipf-biotech-celea-gets-180m-to-follow-paths-of-puretech-s-karuna-seaport-0299ee434050befbPharma Surgeen2026-07-02T14:28:00.000ZIPF biotech Celea gets $180M to follow paths of PureTech’s Karuna, Seaporthttps://www.pharmaradar360.com/article/roche-drug-sets-new-standard-for-kras-driven-lung-cancer-51ea80ca27e7501dPharma Surgeen2026-07-02T14:18:08.000ZRoche drug sets new standard for KRAS-driven lung cancerhttps://www.pharmaradar360.com/article/what-a-brooklyn-bodega-reveals-about-the-craze-for-an-experimental-weight-loss-d-81d53e494ee66a8aPharma Surgeen2026-07-02T14:00:00.000ZWhat a Brooklyn bodega reveals about the craze for an experimental weight-loss drughttps://www.pharmaradar360.com/article/trinity-biotech-reports-positive-clinical-findings-for-next-gen-cgm-e21082a8a77c5d31Pharma Surgeen2026-07-02T13:54:20.000ZTrinity Biotech reports positive clinical findings for next-gen CGMhttps://www.pharmaradar360.com/article/fda-widens-vertex-s-casgevy-use-for-paediatric-patients-f3a1e57292a3844aPharma Surgeen2026-07-02T13:51:55.000ZFDA widens Vertex’s Casgevy use for paediatric patientshttps://www.pharmaradar360.com/article/trinity-biotech-reports-positive-clinical-findings-for-next-gen-cgm-27b9ee0836a21a70Pharma Surgeen2026-07-02T13:49:05.000ZTrinity Biotech reports positive clinical findings for next-gen CGMhttps://www.pharmaradar360.com/article/ipsen-bolsters-rare-disease-pipeline-in-700m-memo-takeover-3707c39fe6078bb2Pharma Surgeen2026-07-02T13:41:15.000ZIpsen bolsters rare disease pipeline in €700m Memo takeoverhttps://www.pharmaradar360.com/article/vrxa-stock-price-news-analysis-2b09819439ca80fePharma Surgeen2026-07-02T13:38:49.000ZVRXA Stock Price, News & Analysishttps://www.pharmaradar360.com/article/7-fda-decisions-to-watch-for-in-q3-d051530733736f17Pharma Surgeen2026-07-02T13:38:40.000Z7 FDA decisions to watch for in Q3https://www.pharmaradar360.com/article/why-animal-models-still-matter-in-drug-development-ad7ac4ea927c6fafPharma Surgeen2026-07-02T13:33:41.000ZWhy animal models still matter in drug developmenthttps://www.pharmaradar360.com/article/an-extra-229-000-deaths-is-that-the-cost-of-us-uk-drugs-deal-ded292d3a9c13fbePharma Surgeen2026-07-02T13:19:31.000ZAn extra 229,000 deaths: Is that the cost of US-UK drugs deal?https://www.pharmaradar360.com/article/biotech-pre-market-pulse-limn-tenx-eltx-swing-big-301c616a52c84bbaPharma Surgeen2026-07-02T13:17:00.000ZBiotech Pre-Market Pulse: LIMN, TENX, ELTX Swing Bighttps://www.pharmaradar360.com/article/the-rwe-communication-gap-that-s-costing-manufacturers-formulary-access-47df01030fbf3832Pharma Surgeen2026-07-02T13:08:16.000ZThe RWE Communication Gap That's Costing Manufacturers Formulary Accesshttps://www.pharmaradar360.com/article/trilogy-laboratories-acquires-yns-cosmeceuticals-bringing-pharmaceutical-experti-4248002ca2eba640Pharma Surgeen2026-07-02T13:02:00.000ZTrilogy Laboratories Acquires YNS Cosmeceuticals, Bringing Pharmaceutical Expertise and Physician Leadership to a Trusted Skincare Brandhttps://www.pharmaradar360.com/article/biotech-investor-pumps-the-brakes-on-ai-drug-discovery-88d76ca530f3fd4cPharma Surgeen2026-07-02T13:00:14.000ZBiotech Investor Pumps the Brakes on AI Drug Discoveryhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-2025-to-2026-695ba9f5e6b7fd05Pharma Surgeen2026-07-02T13:00:02.000ZWeekly all-cause mortality surveillance: 2025 to 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-reports-2025-to-2026-season-d6b3a2494c57cfa7Pharma Surgeen2026-07-02T13:00:02.000ZNational flu and COVID-19 surveillance reports: 2025 to 2026 seasonhttps://www.pharmaradar360.com/article/syndromic-surveillance-weekly-summaries-for-2026-45747e3878253defPharma Surgeen2026-07-02T13:00:02.000ZSyndromic surveillance: weekly summaries for 2026https://www.pharmaradar360.com/article/remote-health-advice-weekly-bulletins-for-2026-0b8fbceac342c05cPharma Surgeen2026-07-02T13:00:02.000ZRemote health advice: weekly bulletins for 2026https://www.pharmaradar360.com/article/national-ambulance-syndromic-surveillance-weekly-bulletins-2026-6dee157afd1fba75Pharma Surgeen2026-07-02T13:00:02.000ZNational ambulance syndromic surveillance: weekly bulletins 2026https://www.pharmaradar360.com/article/gp-out-of-hours-syndromic-surveillance-weekly-bulletins-for-2026-f212a5a75078c06ePharma Surgeen2026-07-02T13:00:02.000ZGP out-of-hours syndromic surveillance: weekly bulletins for 2026https://www.pharmaradar360.com/article/gp-in-hours-weekly-bulletins-for-2026-dfebf391f225843dPharma Surgeen2026-07-02T13:00:02.000ZGP in-hours: weekly bulletins for 2026https://www.pharmaradar360.com/article/emergency-department-weekly-bulletins-for-2026-08abcdde2881ef86Pharma Surgeen2026-07-02T13:00:02.000ZEmergency department: weekly bulletins for 2026https://www.pharmaradar360.com/article/what-s-driving-direct-to-patient-model-adoption-across-pharma-c5fcc588c06173f1Pharma Surgeen2026-07-02T13:00:00.000ZWhat's Driving Direct-to-Patient Model Adoption Across Pharma?https://www.pharmaradar360.com/article/jyong-biotech-presents-drug-candidate-at-bio-2026-convention-8c048da8a228fa51Pharma Surgeen2026-07-02T12:52:36.000ZJyong Biotech presents drug candidate at BIO 2026 conventionhttps://www.pharmaradar360.com/article/what-to-expect-from-west-pharmaceutical-services-q2-2026-earnings-report-c159bdad4417a615Pharma Surgeen2026-07-02T12:34:13.000ZWhat to Expect From West Pharmaceutical Services' Q2 2026 Earnings Reporthttps://www.pharmaradar360.com/article/fosun-pays-32m-to-join-lilly-and-novartis-in-fiercely-competitive-psoriasis-mark-027346c2c56b5e41Pharma Surgeen2026-07-02T12:30:00.000ZFosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis markethttps://www.pharmaradar360.com/article/roche-orchestrates-phase-3-kras-lung-cancer-win-over-amgen-bms-25eeaa042437e631Pharma Surgeen2026-07-02T12:30:00.000ZRoche orchestrates phase 3 KRAS lung cancer win over Amgen, BMShttps://www.pharmaradar360.com/article/spdr-health-care-etf-tops-ishares-biotech-in-long-term-returns-7a704a643a698de6Pharma Surgeen2026-07-02T12:15:01.000ZSPDR Health Care ETF Tops iShares Biotech in Long-Term Returnshttps://www.pharmaradar360.com/article/spdr-health-care-etf-tops-ishares-biotech-in-long-term-returns-9c0e522ff208c41bPharma Surgeen2026-07-02T12:05:01.000ZSPDR Health Care ETF Tops iShares Biotech in Long-Term Returnshttps://www.pharmaradar360.com/article/nkgen-biotech-to-present-at-the-2026-biochina-global-forum-1ab687e3667e6c87Pharma Surgeen2026-07-02T12:05:00.000ZNKGen Biotech to Present at the 2026 BIOCHINA Global Forumhttps://www.pharmaradar360.com/article/late-breaking-esc-2026-spot-for-tenax-tenx-phase-3-level-trial-data-6e67a4c70232dc68Pharma Surgeen2026-07-02T12:01:12.000ZLate-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial datahttps://www.pharmaradar360.com/article/glidesheath-slender-introducer-sheath-8a7af6818d0a8081Pharma Surgeen2026-07-02T12:00:00.000ZGlidesheath Slender® Introducer Sheathhttps://www.pharmaradar360.com/article/fludeoxyglucose-18f-injection-cracket-vial-91714d4a458d5007Pharma Surgeen2026-07-02T12:00:00.000ZFludeoxyglucose (18F) Injection; Cracket vialhttps://www.pharmaradar360.com/article/airseal-access-port-with-blunt-obturator-and-airseal-access-port-with-optical-ob-11dc73defafdedb1Pharma Surgeen2026-07-02T12:00:00.000ZAirSeal Access Port With Blunt Obturator and AirSeal Access Port With Optical Obturatorhttps://www.pharmaradar360.com/article/jyong-biotech-pitched-its-plant-based-bph-drug-to-pharma-partners-at-bio-2026-31a41365b835c2ffPharma Surgeen2026-07-02T12:00:00.000ZJyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026https://www.pharmaradar360.com/article/jyong-biotech-showcases-botanical-drug-portfolio-at-bio-2026-international-conve-1ae151d3ff80d797Pharma Surgeen2026-07-02T12:00:00.000ZJyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Conventionhttps://www.pharmaradar360.com/article/vivani-announces-entry-into-merger-agreement-between-wholly-owned-subsidiary-cor-02abbcb2b62a749bPharma Surgeen2026-07-02T12:00:00.000ZVivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.https://www.pharmaradar360.com/article/pharmaceutical-technology-d80d4b754683513dPharma Surgeen2026-07-02T11:57:00.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/podcast-hlth-europe-and-bio-key-trends-rundown-337303b01579b413Pharma Surgeen2026-07-02T11:48:45.000ZPodcast: HLTH Europe and BIO key trends rundownhttps://www.pharmaradar360.com/article/tenax-therapeutics-to-present-phase-3-trial-results-at-esc-90bbbe23ba6b6f45Pharma Surgeen2026-07-02T11:27:15.000ZTenax Therapeutics to present Phase 3 trial results at ESChttps://www.pharmaradar360.com/article/kane-biotech-announces-results-of-annual-and-special-meeting-of-shareholders-5dc2419e4467d457Pharma Surgeen2026-07-02T11:25:00.000ZKane Biotech Announces Results of Annual and Special Meeting of Shareholdershttps://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-868612ab5086bdedPharma Surgeen2026-07-02T11:06:48.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/thermo-fisher-to-back-arcturus-nasdaq-arct-arct-032-phase-3-and-manufacturing-cc37e9d7b209c515Pharma Surgeen2026-07-02T11:06:24.000ZThermo Fisher to back Arcturus (NASDAQ: ARCT) ARCT-032 Phase 3 and manufacturinghttps://www.pharmaradar360.com/article/china-ai-drug-design-deals-swell-as-us-scrutiny-mounts-25460db6c16037caPharma Surgeen2026-07-02T11:00:10.000ZChina AI drug-design deals swell as US scrutiny mountshttps://www.pharmaradar360.com/article/rare-and-imported-pathogens-laboratory-ripl-user-manual-9019c0801efa285ePharma Surgeen2026-07-02T11:00:01.000ZRare and Imported Pathogens Laboratory (RIPL): user manualhttps://www.pharmaradar360.com/article/veraxa-advances-lead-cancer-drug-toward-manufacturing-work-with-atum-e50939384e0a2961Pharma Surgeen2026-07-02T11:00:00.000ZVERAXA advances lead cancer drug toward manufacturing work with ATUMhttps://www.pharmaradar360.com/article/arcturus-taps-thermo-fisher-to-make-its-cystic-fibrosis-therapy-d47dedd36ac9c659Pharma Surgeen2026-07-02T11:00:00.000ZArcturus taps Thermo Fisher to make its cystic fibrosis therapyhttps://www.pharmaradar360.com/article/tenax-to-present-level-trial-data-at-esc-congress-before-august-results-41f88e0d13e34b76Pharma Surgeen2026-07-02T11:00:00.000ZTenax to present LEVEL trial data at ESC Congress before August resultshttps://www.pharmaradar360.com/article/tenax-therapeutics-announces-late-breaking-presentation-of-level-clinical-trial-5412b80db22ab923Pharma Surgeen2026-07-02T11:00:00.000ZTenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026https://www.pharmaradar360.com/article/arcturus-therapeutics-announces-strategic-collaboration-with-thermo-fisher-scien-648700ed5c0eecbdPharma Surgeen2026-07-02T11:00:00.000ZArcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosishttps://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-0f052de59c1aa164Pharma Surgeen2026-07-02T10:53:43.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/wall-street-thinks-this-biotech-stock-can-soar-45-here-s-why-analysts-are-right-89deca2a7d2873a5Pharma Surgeen2026-07-02T10:53:00.000ZWall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.https://www.pharmaradar360.com/article/analysis-50-cut-in-danish-pharma-production-could-cost-30-000-jobs-9d605be0cc93f389Pharma Surgeen2026-07-02T10:43:07.000ZAnalysis: 50% cut in Danish pharma production could cost 30,000 jobshttps://www.pharmaradar360.com/article/fda-approved-cannabis-why-schedule-3-means-operators-must-prepare-for-pharmaceut-5421ff5c3be320a8Pharma Surgeen2026-07-02T10:33:33.000ZFDA approved cannabis: Why Schedule 3 means operators must prepare for pharmaceutical-grade MMJ nowhttps://www.pharmaradar360.com/article/halfway-into-the-year-biotech-is-booming-4ad98a2294653004Pharma Surgeen2026-07-02T10:33:10.000ZHalfway into the year, biotech is boominghttps://www.pharmaradar360.com/article/adragos-and-towa-to-produce-1-5-billion-tablets-a-year-f7004863d35e1305Pharma Surgeen2026-07-02T10:32:25.000ZAdragos and Towa to Produce 1.5 Billion Tablets a Yearhttps://www.pharmaradar360.com/article/shanghai-fudan-zhangjiang-bio-pharmaceutical-subscribes-structured-deposit-produ-1313e3a1786dc08ePharma Surgeen2026-07-02T10:27:35.000ZShanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes Structured Deposit Product With Amount Of RMB330 MLNhttps://www.pharmaradar360.com/article/astrazeneca-signs-cspc-china-deal-for-experimental-kidney-disease-drugs-44048240c14efde7Pharma Surgeen2026-07-02T10:17:43.000ZAstraZeneca signs CSPC China deal for experimental kidney disease drugshttps://www.pharmaradar360.com/article/us-launches-security-probe-into-five-pharma-giants-doing-clinical-trials-in-chin-bf01c28ba3004ff0Pharma Surgeen2026-07-02T10:08:57.000ZUS launches security probe into five pharma giants doing clinical trials in Chinahttps://www.pharmaradar360.com/article/realistic-timelines-for-pharma-manufacturing-reshoring-4499d498dc4fc84fPharma Surgeen2026-07-02T10:07:30.000ZRealistic Timelines for Pharma Manufacturing Reshoringhttps://www.pharmaradar360.com/article/beyond-attendance-listening-to-children-and-families-about-the-mental-health-sup-8fc7dce79d8042a8Pharma Surgeen2026-07-02T09:59:50.000ZBeyond attendance: Listening to children and families about the mental health support needs of young people not in schoolhttps://www.pharmaradar360.com/article/ipsen-to-buy-swiss-biotech-memo-in-deal-that-could-top-800-million-73876289c22bac33Pharma Surgeen2026-07-02T09:57:40.000ZIpsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Millionhttps://www.pharmaradar360.com/article/tracking-cathie-wood-major-circle-accumulation-and-biotech-cluster-build-up-trim-5a2141d13eb1b68bPharma Surgeen2026-07-02T09:34:59.000ZTracking Cathie Wood: Major Circle Accumulation and Biotech Cluster Build-Up, Trimming Alibaba and Medical Devicehttps://www.pharmaradar360.com/article/abivax-shares-continue-climbing-after-biotech-firm-moves-to-bolster-balance-shee-e082d08952be37f3Pharma Surgeen2026-07-02T09:25:00.000ZAbivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheethttps://www.pharmaradar360.com/article/takeda-insilico-strike-ai-drug-discovery-deal-worth-up-to-600-million-8a76d8e84b7c667aPharma Surgeen2026-07-02T09:22:00.000ZTakeda, Insilico Strike AI Drug-Discovery Deal Worth Up to $600 Millionhttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-to-march-2026-f6bcfb810bad2e74Pharma Surgeen2026-07-02T09:11:07.000ZAdult social care client level data, England: quarterly update to March 2026https://www.pharmaradar360.com/article/new-data-strengthen-cemdisiran-case-in-generalized-mg-e8cb98717488cc34Pharma Surgeen2026-07-02T09:09:55.000ZNew data strengthen cemdisiran case in generalized MGhttps://www.pharmaradar360.com/article/fe68bc0b69958ecaPharma Surgeen2026-07-02T09:02:37.000ZΠΡΟΚΗΡΥΞΗ ΠΛΗΡΩΣΗΣ ΘΕΣΕΩΝhttps://www.pharmaradar360.com/article/can-fite-to-test-namodenoson-in-pancreatic-cancer-d5955ad87e627e35Pharma Surgeen2026-07-02T09:02:20.000ZCan-Fite to test namodenoson in pancreatic cancerhttps://www.pharmaradar360.com/article/china-s-cspc-pharmaceutical-group-to-partner-with-astrazeneca-for-renal-disease-03b24634f4a67ca2Pharma Surgeen2026-07-02T08:55:31.000ZChina's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drughttps://www.pharmaradar360.com/article/lord-mann-review-on-antisemitism-and-other-forms-of-racism-in-the-nhs-7b9c2ee5668e8aacPharma Surgeen2026-07-02T08:54:16.000ZLord Mann review on antisemitism and other forms of racism in the NHShttps://www.pharmaradar360.com/article/medicines-eligible-for-northern-ireland-mhra-authorised-route-ea4846a98bf6c2a7Pharma Surgeen2026-07-02T08:51:10.000ZMedicines eligible for Northern Ireland MHRA Authorised Routehttps://www.pharmaradar360.com/article/safeguarding-uk-human-genomic-data-db7284ae2e26255dPharma Surgeen2026-07-02T08:44:54.000ZSafeguarding UK human genomic datahttps://www.pharmaradar360.com/article/glenmark-initiates-phase-3-trial-of-1-billion-cancer-buyout-trastuzumab-rezeteca-d24451c9ec4fce14Pharma Surgeen2026-07-02T08:42:04.000ZGlenmark initiates Phase 3 trial of $1 billion Cancer buyout Trastuzumab rezetecanhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-enters-collaboration-option-license-agreement-with-astrazene-6c9836bc12282393Pharma Surgeen2026-07-02T08:35:45.000ZCSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugshttps://www.pharmaradar360.com/article/research-mhra-data-requirements-to-support-regulatory-decision-making-9c0cc286a346a7d3Pharma Surgeen2026-07-02T08:34:28.000ZResearch: MHRA data requirements to support regulatory decision makinghttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-02T08:30:07.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-02T08:30:07.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/sexually-transmitted-infections-london-data-927003b4155f03a8Pharma Surgeen2026-07-02T08:30:06.000ZSexually transmitted infections: London datahttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-b306771583db51dfPharma Surgeen2026-07-02T08:30:05.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in Englandhttps://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-e72ee03f6bc9d959Pharma Surgeen2026-07-02T08:30:05.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in Englandhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-surveillance-reports-2025-to-2026-season-1192c065abd24222Pharma Surgeen2026-07-02T08:30:05.000ZNational norovirus and rotavirus surveillance reports: 2025 to 2026 seasonhttps://www.pharmaradar360.com/article/pre-release-access-lists-national-norovirus-and-rotavirus-surveillance-reports-f8340eaf52659afdPharma Surgeen2026-07-02T08:30:05.000ZPre-release access lists: National norovirus and rotavirus surveillance reportshttps://www.pharmaradar360.com/article/adult-social-care-client-level-data-england-quarterly-update-1b4c313e4093d4bbPharma Surgeen2026-07-02T08:30:05.000ZAdult social care client level data, England: quarterly updatehttps://www.pharmaradar360.com/article/borderline-products-how-to-tell-if-your-product-is-a-medicine-ce4e68ea226f4c9cPharma Surgeen2026-07-02T08:27:17.000ZBorderline products: how to tell if your product is a medicinehttps://www.pharmaradar360.com/article/gc-biopharma-starts-korea-phase-3-for-two-dose-varicella-vaccine-chosunbiz-6f38d50c2cd21a53Pharma Surgeen2026-07-02T08:25:00.000ZGC Biopharma starts Korea phase 3 for two-dose varicella vaccine - CHOSUNBIZhttps://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-86062f304e916685Pharma Surgeen2026-07-02T08:24:22.000ZDecision: Human medicines: register of electronic export certificateshttps://www.pharmaradar360.com/article/ia-global-asset-management-inc-purchases-91-026-shares-of-teva-pharmaceutical-in-ed3e4304ef77b239Pharma Surgeen2026-07-02T08:22:07.000ZiA Global Asset Management Inc. Purchases 91,026 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/bii-takes-next-step-in-its-european-expansion-joins-new-italy-focused-venture-fu-882656ce46f9695aPharma Surgeen2026-07-02T08:19:00.000ZBII takes next step in its European expansion: Joins new Italy-focused venture fundhttps://www.pharmaradar360.com/article/top-10-sustainable-pharmaceutical-companies-573d0588902be79ePharma Surgeen2026-07-02T08:08:42.000ZTop 10: Sustainable Pharmaceutical Companieshttps://www.pharmaradar360.com/article/device-name-non-sterile-folded-gauze-yancheng-zaichuang-medical-supplies-co-ltd-a4989f9f74481525Pharma Surgeen2026-07-02T07:59:55.000ZΑνάκληση από την αγορά των προϊόντων με Device name: «Non-sterile folded gauze», της κατασκευάστριας εταιρείας YANCHENG ZAICHUANG MEDICAL SUPPLIES CO LTD (Κίνας) (Εξουσ. Αντιπρ. για την Ε.Ε. MedPath GmbH (Γερμανία)), τα οποία συνοδεύονται από παραποιημένη δήλωση συμμόρφωσης του κατασκευαστή.https://www.pharmaradar360.com/article/glenmark-advances-multi-country-phase-3-trial-of-trastuzumab-rezetecan-in-platin-65091022136350aaPharma Surgeen2026-07-02T07:18:47.000ZGlenmark Advances Multi-Country Phase 3 Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancerhttps://www.pharmaradar360.com/article/glenmark-advances-multi-country-phase-3-clinical-trial-of-trastuzumab-rezetecan-6bb4c5d02b7fd2f2Pharma Surgeen2026-07-02T07:15:50.000ZGlenmark advances multi-country phase 3 clinical trial of Trastuzumab rezetecan in PROChttps://www.pharmaradar360.com/article/platform-technologies-could-drive-korean-biotech-rebound-in-h2-analyst-59b9f8fed4c5911bPharma Surgeen2026-07-02T07:15:44.000ZPlatform technologies could drive Korean biotech rebound in H2: analysthttps://www.pharmaradar360.com/article/the-future-of-biotech-bridgebio-ionis-and-biomarin-are-worth-watching-f3be70d02109e89fPharma Surgeen2026-07-02T06:39:04.000ZThe Future of Biotech? BridgeBio, Ionis and BioMarin Are Worth Watchinghttps://www.pharmaradar360.com/article/divarasib-iii-krascendo1-3c6e741c25d0693aPharma Surgeen2026-07-02T06:30:00.000Zロシュ社によるdivarasibに関する発表について（第III相Krascendo1試験結果）https://www.pharmaradar360.com/article/roche-s-announcement-regarding-divarasib-announcement-of-phase-iii-krascendo1-st-611cfbc63452a5c0Pharma Surgeen2026-07-02T06:30:00.000ZRoche’s Announcement Regarding divarasib (Announcement of Phase III Krascendo1 Study Results)https://www.pharmaradar360.com/article/ad-hoc-announcement-pursuant-to-art-53-lr-roche-s-divarasib-shows-superiority-in-255702641dea2184Pharma Surgeen2026-07-02T05:00:00.000Z[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancerhttps://www.pharmaradar360.com/article/telix-clears-fda-protocol-review-for-prostate-cancer-trial-expansion-133e34d72ff7e03fPharma Surgeen2026-07-02T04:12:25.000ZTelix clears FDA protocol review for prostate cancer trial expansionhttps://www.pharmaradar360.com/article/glenmark-advances-phase-3-cancer-trial-shares-edge-higher-7e578a6d72d1a111Pharma Surgeen2026-07-02T04:11:45.000ZGlenmark Advances Phase 3 Cancer Trial; Shares Edge Higherhttps://www.pharmaradar360.com/article/telix-pharmaceuticals-aligns-with-fda-on-phase-3-trial-6728f3023b91ac23Pharma Surgeen2026-07-02T03:47:33.000ZTelix Pharmaceuticals aligns with FDA on Phase 3 trialhttps://www.pharmaradar360.com/article/glenmark-pharma-wins-india-s-1st-phase-3-approval-for-trastuzumab-rezetecan-canc-1854556ff44ce431Pharma Surgeen2026-07-02T03:39:12.000ZGlenmark Pharma Wins India's 1st Phase 3 Approval for Trastuzumab Rezetecan Cancer Trialhttps://www.pharmaradar360.com/article/ecowaste-coalition-echoes-fda-b-e-a-t-reminders-on-musical-toys-2a3d5dd49c522bd3Pharma Surgeen2026-07-02T03:33:51.000ZEcoWaste Coalition Echoes FDA B.E.A.T. Reminders on Musical Toyshttps://www.pharmaradar360.com/article/glenmark-s-trastuzumab-rezetecan-phase-3-trial-for-ovarian-cancer-gets-dcgi-nod-67b0941aa5a4ccf0Pharma Surgeen2026-07-02T03:18:02.000ZGlenmark's Trastuzumab Rezetecan Phase 3 Trial for Ovarian Cancer Gets DCGI Nodhttps://www.pharmaradar360.com/article/gc-biopharma-announced-on-the-2nd-that-the-phase-3-clinical-trial-plan-ind-for-t-675ff4d614b23473Pharma Surgeen2026-07-02T01:49:56.000ZGC Biopharma announced on the 2nd that the phase 3 clinical trial plan (IND) for the chickenpox vacc..https://www.pharmaradar360.com/article/fda-alignment-to-advance-prostact-global-phase-3-trial-13ca93648e506c85Pharma Surgeen2026-07-02T01:36:50.000ZFDA Alignment to Advance ProstACT Global Phase 3 Trialhttps://www.pharmaradar360.com/article/anthropic-debuts-ai-driven-pharma-r-d-tool-claude-science-56a0a3b20209f8d7Pharma Surgeen2026-07-02T01:32:55.000ZAnthropic debuts AI-driven pharma R&D tool, Claude Sciencehttps://www.pharmaradar360.com/article/fda-alignment-to-advance-prostact-global-phase-3-trial-35ad7ca9e2debf8bPharma Surgeen2026-07-02T01:31:00.000ZFDA Alignment to Advance ProstACT Global Phase 3 Trialhttps://www.pharmaradar360.com/article/gni-group-completes-acquisition-of-ayumi-pharmaceutical-ee10e05a4cbf695fPharma Surgeen2026-07-02T01:07:00.000ZGNI Group Completes Acquisition of AYUMI Pharmaceuticalhttps://www.pharmaradar360.com/article/the-pill-that-is-being-used-against-women-the-fda-must-act-on-mifepristone-50e498e1d8205d04Pharma Surgeen2026-07-02T01:02:35.000ZThe pill that is being used against women: The FDA must act on mifepristone.https://www.pharmaradar360.com/article/insilico-keeps-partnership-sprint-apace-in-600m-biobucks-collab-with-takeda-156273267561fa77Pharma Surgeen2026-07-02T00:30:00.000ZInsilico keeps partnership sprint apace in $600M biobucks collab with Takedahttps://www.pharmaradar360.com/article/a-guide-to-sarms-definition-side-effects-and-dangers-e67630b4d57afdc1Pharma Surgeen2026-07-02T00:20:52.000ZA Guide to SARMs: Definition, Side Effects, and Dangershttps://www.pharmaradar360.com/article/cytiva-executive-on-biotech-trends-challenges-and-innovation-1d92fbd027a5daf9Pharma Surgeen2026-07-02T00:09:18.000ZCytiva executive on biotech Trends, challenges, and innovationhttps://www.pharmaradar360.com/article/taiho-innovations-begins-operations-under-new-organizational-structure-establish-4dfbbb700f832621Pharma Surgeen2026-07-02T00:00:00.000ZTaiho Innovations Begins Operations Under New Organizational Structure Establishing an Early Clinical Development Function to Strengthen Its Co-Creation Platformhttps://www.pharmaradar360.com/article/otsuka-reports-positive-phase-3-visionary-two-year-egfr-results-demonstrating-vo-08039329e5a6a919Pharma Surgeen2026-07-02T00:00:00.000ZOtsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-ee22597b75525531Pharma Surgeen2026-07-02T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-080a74eeccf75ab3Pharma Surgeen2026-07-02T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-54f42536cbf57580Pharma Surgeen2026-07-02T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-3ff39f3cff4365d0Pharma Surgeen2026-07-02T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-abdcba83e74d9804Pharma Surgeen2026-07-02T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-1de170e402a168d1Pharma Surgeen2026-07-02T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-39c7168a2aa65e81Pharma Surgeen2026-07-02T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-4236731d6191b012Pharma Surgeen2026-07-02T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-a3a430ef08c7beeePharma Surgeen2026-07-02T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-a0f3f83387bb958cPharma Surgeen2026-07-02T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-f50b47dbacce5e3cPharma Surgeen2026-07-02T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-30478ec9531fc7d7Pharma Surgeen2026-07-02T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-10924060f7aeb351Pharma Surgeen2026-07-02T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-2a9d2a05f6903aa4Pharma Surgeen2026-07-02T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-a-conserved-viral-peptide-for-u-fdfb6513dd337995Pharma Surgeen2026-07-02T00:00:00.000ZGovernment Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapyhttps://www.pharmaradar360.com/article/government-owned-invention-available-for-license-chimeric-vlp-vaccines-to-preven-5d6ec30cad77df0cPharma Surgeen2026-07-02T00:00:00.000ZGovernment Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infectionhttps://www.pharmaradar360.com/article/agency-information-collection-request-60-day-public-comment-request-2b832cc42af17e1bPharma Surgeen2026-07-02T00:00:00.000ZAgency Information Collection Request. 60-Day Public Comment Requesthttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-cca1c23850ef3f5bPharma Surgeen2026-07-02T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/reducing-bureaucracy-and-burden-for-children-youth-and-family-programs-ab049ee995abaf55Pharma Surgeen2026-07-02T00:00:00.000ZReducing Bureaucracy and Burden for Children, Youth, and Family Programshttps://www.pharmaradar360.com/article/current-list-of-hhs-certified-laboratories-and-instrumented-initial-testing-faci-4e1a0af7e0073f40Pharma Surgeen2026-07-02T00:00:00.000ZCurrent List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencieshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-chafee-strengthening-outco-395067dd2646fad6Pharma Surgeen2026-07-02T00:00:00.000ZSubmission for Office of Management and Budget Review; Chafee Strengthening Outcomes for Transition to Adulthood Project Overarching Generic (Extension)https://www.pharmaradar360.com/article/termination-of-declaration-authorizing-emergency-use-of-drug-and-biological-prod-7e0ae55228bc17c9Pharma Surgeen2026-07-02T00:00:00.000ZTermination of Declaration Authorizing Emergency Use of Drug and Biological Products During the COVID-19 Pandemichttps://www.pharmaradar360.com/article/termination-of-three-declarations-authorizing-emergency-use-of-medical-devices-d-a0a9a6d9b6d35868Pharma Surgeen2026-07-02T00:00:00.000ZTermination of Three Declarations Authorizing Emergency Use of Medical Devices During the COVID-19 Pandemichttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-office-of-refugee-resettle-b0a20fca6eaa8375Pharma Surgeen2026-07-02T00:00:00.000ZSubmission for Office of Management and Budget Review; Office of Refugee Resettlement Annual Survey of Refugeeshttps://www.pharmaradar360.com/article/united-therapeutics-corporation-acquires-thymmune-therapeutics-907f7bca31986c27Pharma Surgeen2026-07-02T00:00:00.000ZUnited Therapeutics Corporation Acquires Thymmune Therapeuticshttps://www.pharmaradar360.com/article/antioxidant-and-anti-apoptotic-activities-of-makiang-fruit-extract-in-arpe-19-ce-d05bfdaf801ea420Pharma Surgeen2026-07-02T00:00:00.000ZANTIOXIDANT AND ANTI-APOPTOTIC ACTIVITIES OF MAKIANG FRUIT EXTRACT IN ARPE-19 CELLS EXPOSED TO GLUCOSE-INDUCED CELLULAR DAMAGEhttps://www.pharmaradar360.com/article/super-resolution-visual-proteomex-for-hard-tissues-and-clinical-samples-29a1a5dd0ff9fe35Pharma Surgeen2026-07-02T00:00:00.000ZSuper-Resolution Visual ProteomEx for Hard Tissues and Clinical Sampleshttps://www.pharmaradar360.com/article/holmium-lithotripsy-laser-assisted-endoscopic-retrieval-of-a-fish-bone-impacted-a59459682ba46fe1Pharma Surgeen2026-07-02T00:00:00.000ZHolmium lithotripsy laser-assisted endoscopic retrieval of a fish bone impacted in the esophagus: a rare extraction techniquehttps://www.pharmaradar360.com/article/opioid-free-anesthesia-current-evidence-clinical-applications-and-future-perspec-c2fd916d848d0d24Pharma Surgeen2026-07-02T00:00:00.000ZOpioid-Free Anesthesia: Current Evidence, Clinical Applications, and Future Perspectiveshttps://www.pharmaradar360.com/article/culture-conversion-and-drug-susceptibility-in-drug-resistant-pulmonary-tuberculo-760f453f0ef28ed1Pharma Surgeen2026-07-02T00:00:00.000ZCulture conversion and drug susceptibility in drug resistant pulmonary tuberculosis with type II diabetes mellitus on oral regimenshttps://www.pharmaradar360.com/article/cardiac-arrest-in-an-adolescent-following-an-overdose-of-antidepressants-compris-429654b521db13b5Pharma Surgeen2026-07-02T00:00:00.000ZCardiac arrest in an adolescent following an overdose of antidepressants comprising sertraline, quetiapine fumarate, and lamotrigine: Case reporthttps://www.pharmaradar360.com/article/staged-surgical-treatment-of-giant-renal-angiomyolipoma-with-preoperative-emboli-4bb8c63e574aeaa3Pharma Surgeen2026-07-02T00:00:00.000ZSTAGED SURGICAL TREATMENT OF GIANT RENAL ANGIOMYOLIPOMA WITH PREOPERATIVE EMBOLIZATION OF THE RENAL ARTERY: A CLINICAL CASEhttps://www.pharmaradar360.com/article/the-friend-to-friend-program-97e2b50f662fd4f7Pharma Surgeen2026-07-02T00:00:00.000ZThe Friend to Friend Programhttps://www.pharmaradar360.com/article/adapting-the-coping-power-program-33cb8cb37bd96f2aPharma Surgeen2026-07-02T00:00:00.000ZAdapting the Coping Power Programhttps://www.pharmaradar360.com/article/irreversible-electroporation-for-the-treatment-of-pediatric-adenotonsillar-hyper-4ddd3f6866c0b0e8Pharma Surgeen2026-07-02T00:00:00.000ZIrreversible Electroporation for the Treatment of Pediatric Adenotonsillar Hypertrophyhttps://www.pharmaradar360.com/article/objective-tongue-function-outcomes-after-lingual-frenotomy-with-adjunctive-myofa-67635f27e0f8747ePharma Surgeen2026-07-02T00:00:00.000ZObjective Tongue-Function Outcomes After Lingual Frenotomy with Adjunctive Myofascial Rehabilitation: A Retrospective Observational Longitudinal Studyhttps://www.pharmaradar360.com/article/upper-urinary-system-changes-after-radical-cystectomy-and-bricker-urinary-divers-a643162a83e49121Pharma Surgeen2026-07-02T00:00:00.000ZUpper Urinary System Changes After Radical Cystectomy and Bricker Urinary Diversion: A Retrospective Evaluation of Functional and Radiological Parametershttps://www.pharmaradar360.com/article/glasgow-prognostic-score-and-gustave-roussy-immune-score-in-hodgkin-lymphoma-sur-9629ba1b8f22f5e0Pharma Surgeen2026-07-02T00:00:00.000ZGlasgow Prognostic Score and Gustave Roussy Immune Score in Hodgkin Lymphoma: Survival Associations and Limited Incremental Prognostic Value Beyond the International Prognostic Scorehttps://www.pharmaradar360.com/article/correction-yang-et-al-5-methylcytidine-rna-epitranscriptomics-in-women-s-health-d24be795c524397fPharma Surgeen2026-07-02T00:00:00.000ZCorrection: Yang et al. 5-Methylcytidine RNA Epitranscriptomics in Women’s Health and Disease: Mechanisms and Clinical Implications. Cells 2026, 15, 847https://www.pharmaradar360.com/article/implementation-of-sequencing-based-surveillance-for-drug-resistant-tuberculosis-5ff39f3ad424ec39Pharma Surgeen2026-07-02T00:00:00.000ZImplementation of sequencing-based surveillance for drug-resistant tuberculosis in Nigeriahttps://www.pharmaradar360.com/article/dynamic-phenotype-monitoring-to-prevent-genotype-phenotype-discrepancies-in-phar-5f187576059b858dPharma Surgeen2026-07-02T00:00:00.000ZDynamic phenotype monitoring to prevent genotype–phenotype discrepancies in pharmacogenetic-guided drug therapyhttps://www.pharmaradar360.com/article/severe-hepatotoxicity-associated-with-orlistat-clinical-presentation-risk-factor-cd086735ad04390dPharma Surgeen2026-07-02T00:00:00.000ZSevere hepatotoxicity associated with orlistat: clinical presentation, risk factors and outcomeshttps://www.pharmaradar360.com/article/prediction-of-histological-grading-in-ductal-carcinoma-in-situ-based-on-mammogra-1ebbbb6389f7986cPharma Surgeen2026-07-02T00:00:00.000ZPrediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning modelshttps://www.pharmaradar360.com/article/implications-of-autolysosome-astrocyte-associated-signature-in-the-pathogenesis-eb73fa37f04a3d1dPharma Surgeen2026-07-02T00:00:00.000ZImplications of autolysosome- astrocyte-associated signature in the pathogenesis of Alzheimer’s disease: evidence from artificial intelligence and multi-omics and clinical validationhttps://www.pharmaradar360.com/article/an-efficient-micropropagation-protocol-and-optimization-of-phytohormones-for-gla-28763d8feddb800ePharma Surgeen2026-07-02T00:00:00.000ZAn Efficient Micropropagation Protocol and Optimization of Phytohormones for Gladiolus Species for Commercial Cultivationhttps://www.pharmaradar360.com/article/in-vitro-mass-propagation-protocol-for-lobelia-chinensis-lour-optimization-of-gr-8007a4484587e2aaPharma Surgeen2026-07-02T00:00:00.000ZIn vitro Mass Propagation Protocol for Lobelia chinensis Lour.: Optimization of Growth Regulators and Acclimatizationhttps://www.pharmaradar360.com/article/effect-of-scaffold-of-bioactive-glass-in-the-treatment-of-periodontal-bony-defec-ca24cb915d28c40aPharma Surgeen2026-07-02T00:00:00.000ZEffect of Scaffold of Bioactive Glass in the Treatment of Periodontal Bony Defects. A Prospective Clinical Studyhttps://www.pharmaradar360.com/article/awareness-educational-needs-and-curriculum-preferences-regarding-ai-and-medical-f7ef6bd72bf4a33ePharma Surgeen2026-07-02T00:00:00.000ZAwareness, Educational Needs, and Curriculum Preferences Regarding AI and Medical Big Data Education Among Clinical Medicine Undergraduates: Cross-Sectional Survey Studyhttps://www.pharmaradar360.com/article/furosemide-initiation-during-norepinephrine-infusion-and-proximal-hemodynamic-de-bd3720e4f59f50e9Pharma Surgeen2026-07-02T00:00:00.000ZFurosemide initiation during norepinephrine infusion and proximal hemodynamic destabilization: a target trial emulation in MIMIC-IV with external validation in eICU-CRDhttps://www.pharmaradar360.com/article/development-and-internal-validation-of-a-clinical-decision-support-nomogram-for-1b268b8263618e30Pharma Surgeen2026-07-02T00:00:00.000ZDevelopment and Internal Validation of a Clinical Decision Support Nomogram for Predicting Neonatal Intensive Care Unit Admission in Late-Onset Preeclampsiahttps://www.pharmaradar360.com/article/emerging-blood-based-diagnostic-strategies-for-tuberculosis-c3ac7e3719b95ce6Pharma Surgeen2026-07-02T00:00:00.000ZEmerging blood-based diagnostic strategies for tuberculosishttps://www.pharmaradar360.com/article/fixed-drug-eruption-a-case-series-clinical-presentation-and-management-strategie-dc3746283ecdb5fdPharma Surgeen2026-07-02T00:00:00.000ZFixed drug eruption: A case series, clinical presentation and management strategieshttps://www.pharmaradar360.com/article/a-single-dose-of-azithromycin-and-inflammation-in-infants-a-cluster-randomized-p-0a103273567545abPharma Surgeen2026-07-02T00:00:00.000ZA Single Dose of Azithromycin and Inflammation in Infants – A Cluster Randomized Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/primary-knee-osteoarthritis-do-the-clinical-and-functional-outcomes-of-intra-art-f5a6352b4d99c767Pharma Surgeen2026-07-02T00:00:00.000ZPrimary knee osteoarthritis: do the clinical and functional outcomes of intra-articular PRP correlate with MRI structural changes?https://www.pharmaradar360.com/article/correction-nanovaccines-with-ferroptosis-necroptosis-and-sting-activation-for-sy-0a43114f5a60c1e0Pharma Surgeen2026-07-02T00:00:00.000ZCorrection: Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapyhttps://www.pharmaradar360.com/article/rare-emergence-of-delamanid-resistance-in-multidrug-rifampicin-resistant-tubercu-66ea86eb4dd80583Pharma Surgeen2026-07-02T00:00:00.000ZRare emergence of delamanid resistance in multidrug-/rifampicin-resistant tuberculosis patients receiving delamanid-containing regimens: a prospective multicentric study in Chinahttps://www.pharmaradar360.com/article/technical-and-clinical-feasibility-of-single-use-gastroscopy-with-real-time-ai-b-23d841fbdab544d2Pharma Surgeen2026-07-02T00:00:00.000ZTechnical and clinical feasibility of single-use gastroscopy with real-time AI-based quality monitoring and single-use colonoscopy: a prospective two-center studyhttps://www.pharmaradar360.com/article/molecular-prevalence-and-clinical-profiles-of-canine-babesiosis-in-northern-indi-b68158f658b02609Pharma Surgeen2026-07-02T00:00:00.000ZMolecular prevalence and clinical profiles of canine babesiosis in northern Indiahttps://www.pharmaradar360.com/article/artificial-intelligence-assisted-telemedicine-clinical-decision-support-for-anes-ee311f6769247f67Pharma Surgeen2026-07-02T00:00:00.000ZArtificial intelligence assisted telemedicine, clinical decision support for anesthesia and critical care in intensive care units: a scoping reviewhttps://www.pharmaradar360.com/article/health-education-barriers-for-ghanaian-parents-of-children-with-cleft-lip-and-pa-8e94db257875fa7dPharma Surgeen2026-07-02T00:00:00.000ZHealth Education Barriers for Ghanaian Parents of Children with Cleft Lip and Palate: Qualitative Studyhttps://www.pharmaradar360.com/article/invited-commentary-using-large-clinical-databases-1af5bbeeed62795cPharma Surgeen2026-07-02T00:00:00.000ZInvited Commentary: Using Large Clinical Databaseshttps://www.pharmaradar360.com/article/t-bet-expression-in-b-cell-subsets-association-with-t-peripheral-helper-cells-an-9598c40465989e40Pharma Surgeen2026-07-02T00:00:00.000ZT-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosushttps://www.pharmaradar360.com/article/safety-and-feasibility-of-moderate-intensity-home-based-guided-exercise-in-aorti-f5a8bb0281b56de7Pharma Surgeen2026-07-02T00:00:00.000ZSafety and Feasibility of Moderate-Intensity Home-Based Guided Exercise in Aortic Dissection Survivors in the United States: A Multicenter Randomized Controlled Trialhttps://www.pharmaradar360.com/article/abstract-p87-drug-induced-hyperactivation-of-the-oncogene-kras-induces-ferroptos-71281cf0161ff8ccPharma Surgeen2026-07-02T00:00:00.000ZAbstract P87: Drug-induced Hyperactivation of the oncogene KRAS induces ferroptosis in G12-mutant KRAS Pancreatic Ductal Adenocarcinoma (PDAC)https://www.pharmaradar360.com/article/abstract-p69-covalent-inhibition-of-clic1-a-novel-strategy-for-anti-cancer-drug-4f6a132ca5e241c3Pharma Surgeen2026-07-02T00:00:00.000ZAbstract P69: Covalent Inhibition of CLIC1: A Novel Strategy for Anti-Cancer Drug Discoveryhttps://www.pharmaradar360.com/article/data-from-preclinical-to-clinical-translation-of-pharmacokinetic-pharmacodynamic-3e8b513f92732e4ePharma Surgeen2026-07-02T00:00:00.000ZData from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-figure-10-from-preclinical-to-clinical-translation-of-pharmacokine-5bd6759e0347cbd3Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Figure 10 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-figure-4-from-preclinical-to-clinical-translation-of-pharmacokinet-423a20508f0e8cc8Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Figure 4 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-figure-6-from-preclinical-to-clinical-translation-of-pharmacokinet-57ba3a7465cbeb37Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Figure 6 from Preclinical to Clinical Translation of Pharmacokinetic–Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitorshttps://www.pharmaradar360.com/article/supplementary-fig-1-from-identification-and-preclinical-evaluation-of-a-novel-gd-6015f40ff0fceacdPharma Surgeen2026-07-02T00:00:00.000ZSupplementary Fig.1 from Identification and Preclinical Evaluation of a Novel GD2 Antibody–Drug Conjugate for Solid Tumors in Children and Adultshttps://www.pharmaradar360.com/article/supplementary-fig-6-from-identification-and-preclinical-evaluation-of-a-novel-gd-fa62d1cb061d87d2Pharma Surgeen2026-07-02T00:00:00.000ZSupplementary Fig.6 from Identification and Preclinical Evaluation of a Novel GD2 Antibody–Drug Conjugate for Solid Tumors in Children and Adultshttps://www.pharmaradar360.com/article/a-service-evaluation-of-a-specialist-multi-disciplinary-weight-management-servic-b874981b1f88941aPharma Surgeen2026-07-02T00:00:00.000ZA Service Evaluation of a Specialist Multi‐Disciplinary Weight Management Service Based in Primary Care Including Long‐Term Follow‐Up Datahttps://www.pharmaradar360.com/article/cardiopulmonary-exercise-testing-in-australia-and-new-zealand-a-survey-of-curren-afa33545766f7d71Pharma Surgeen2026-07-02T00:00:00.000ZCardiopulmonary Exercise Testing in Australia and New Zealand: A SURVEY OF CURRENT CLINICAL PRACTICEhttps://www.pharmaradar360.com/article/3dice-interpretable-3d-cross-modal-learning-for-drug-target-interaction-predicti-0dcf8a17d0ba40b2Pharma Surgeen2026-07-02T00:00:00.000Z3DICE: Interpretable 3D Cross-Modal Learning for Drug–Target Interaction Prediction and Large-Scale Drug Discoveryhttps://www.pharmaradar360.com/article/clinical-and-healthcare-resource-utilization-outcomes-following-revision-knee-ar-f2838c0463f52223Pharma Surgeen2026-07-02T00:00:00.000ZClinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee systemhttps://www.pharmaradar360.com/article/endomyocardial-gremlin-1-is-associated-with-structural-remodeling-and-adverse-cl-f5f05ac2fd339304Pharma Surgeen2026-07-02T00:00:00.000ZEndomyocardial Gremlin-1 is associated with structural remodeling and adverse clinical outcomes in non-ischemic cardiomyopathyhttps://www.pharmaradar360.com/article/bacillus-calmette-guerin-bcg-immunotherapy-reprograms-cns-immunity-and-alters-al-78c73a112c9d5eb4Pharma Surgeen2026-07-02T00:00:00.000ZBacillus Calmette–Guérin (BCG) immunotherapy reprograms CNS immunity and alters Alzheimer’s biomarkers: results from two open-label clinical trialshttps://www.pharmaradar360.com/article/designing-reuse-models-for-clinical-trial-packaging-to-stimulate-the-transition-022b36f8ac8a3c45Pharma Surgeen2026-07-02T00:00:00.000ZDesigning reuse models for clinical trial packaging to stimulate the transition towards a circular economyhttps://www.pharmaradar360.com/article/cambridge-studies-in-law-and-society-cbdecca2319032a2Pharma Surgeen2026-07-02T00:00:00.000ZCambridge Studies in Law and Societyhttps://www.pharmaradar360.com/article/bibliography-0e3e266cd76477a4Pharma Surgeen2026-07-02T00:00:00.000ZBibliographyhttps://www.pharmaradar360.com/article/clinical-significance-and-predictive-factors-of-delayed-gastric-conduit-emptying-222dbef79e4cabfePharma Surgeen2026-07-02T00:00:00.000ZClinical significance and predictive factors of delayed gastric conduit emptying after esophagectomyhttps://www.pharmaradar360.com/article/mri-based-normative-orbital-anthropometric-measurements-in-pediatric-populations-bed78d4d82ba588fPharma Surgeen2026-07-02T00:00:00.000ZMRI-based normative orbital anthropometric measurements in pediatric populations: age-related variations and clinical implicationshttps://www.pharmaradar360.com/article/validation-of-the-investigator-s-global-assessment-scale-for-epidermolysis-bullo-d9b1cadb5b0ba8ddPharma Surgeen2026-07-02T00:00:00.000ZValidation of the Investigator's Global Assessment Scale for Epidermolysis Bullosa Simplexhttps://www.pharmaradar360.com/article/comparative-risk-of-ventricular-arrhythmia-and-sudden-cardiac-death-among-acetyl-53afbaf1247b1397Pharma Surgeen2026-07-02T00:00:00.000ZComparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population‐based cohort studyhttps://www.pharmaradar360.com/article/nct07682272-a-trial-of-shr-8068-combined-with-adebrelimab-and-apatinib-in-periop-f7106a01d673651cPharma Surgeen2026-07-02T00:00:00.000ZNCT07682272: A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinomahttps://www.pharmaradar360.com/article/nct07681245-label-free-femtosecond-laser-imaging-combined-with-the-fast-lung-art-7b4fcb6f61252c91Pharma Surgeen2026-07-02T00:00:00.000ZNCT07681245: Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.https://www.pharmaradar360.com/article/nct07680764-a-study-to-assess-the-safety-tolerability-and-efficacy-of-imzokitug-f0c9651b7105643cPharma Surgeen2026-07-02T00:00:00.000ZNCT07680764: A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)https://www.pharmaradar360.com/article/nct07680465-prevalence-of-pelvic-venous-congestion-syndrome-in-female-patients-w-cd994f421a5702d5Pharma Surgeen2026-07-02T00:00:00.000ZNCT07680465: Prevalence of Pelvic Venous Congestion Syndrome in Female Patients With Lower Extremity Varicose Veins and Its Impact on Postoperative Quality of Life Improvement Following Radiofrequency Ablation: A Single-Center Prospective Cohort Study（PCSRFStudy）https://www.pharmaradar360.com/article/nct07680439-illuminate-a-clinical-study-evaluating-car-t-immune-cell-therapy-bcb-7c8e1ac6bd27eb62Pharma Surgeen2026-07-02T00:00:00.000ZNCT07680439: Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).https://www.pharmaradar360.com/article/nct07669545-risk-stratification-and-treatment-decisions-in-infantile-hemangioma-e3723b6ef6e633d5Pharma Surgeen2026-07-02T00:00:00.000ZNCT07669545: Risk Stratification and Treatment Decisions in Infantile Hemangioma With Minimal or Arrested Growthhttps://www.pharmaradar360.com/article/nct07663539-insights-from-bereaved-parents-and-oncologists-69e138df59add071Pharma Surgeen2026-07-02T00:00:00.000ZNCT07663539: Insights From Bereaved Parents and Oncologistshttps://www.pharmaradar360.com/article/nct07632638-safety-and-performance-evaluation-of-the-ronovotm-robotic-surgical-p-62eac26bf70d7d7bPharma Surgeen2026-07-02T00:00:00.000ZNCT07632638: Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedureshttps://www.pharmaradar360.com/article/nct07501754-use-of-a-custom-made-acrylic-palatal-stent-to-minimize-donor-site-mo-76d2142262dc0930Pharma Surgeen2026-07-02T00:00:00.000ZNCT07501754: Use of a Custom-Made Acrylic Palatal Stent to Minimize Donor Site Morbidity After Suture-Free Epithelialized Gingival Graft Harvesting: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct07270562-orbital-atherectomy-for-lesion-preparation-in-patients-with-chronic-1ba745e1a8ee7ef2Pharma Surgeen2026-07-02T00:00:00.000ZNCT07270562: ORbital Atherectomy for Lesion Preparation in Patients With Chronic Limb-threatening ischEmiahttps://www.pharmaradar360.com/article/nct07221500-a-study-of-nx-5948-in-adults-with-cll-sll-previously-treated-with-a-1f0d3aa702d269b9Pharma Surgeen2026-07-02T00:00:00.000ZNCT07221500: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)https://www.pharmaradar360.com/article/nct07154745-a-study-to-evaluate-how-pozelimab-cemdisiran-combination-therapy-wor-7cc30921f97e236aPharma Surgeen2026-07-02T00:00:00.000ZNCT07154745: A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficientlyhttps://www.pharmaradar360.com/article/nct06859255-in-vitro-benchmarking-of-currently-available-heart-valve-prostheses-29eefbf2e2d3ed45Pharma Surgeen2026-07-02T00:00:00.000ZNCT06859255: In-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validationhttps://www.pharmaradar360.com/article/nct06783309-cnp-103-in-adolescent-and-adult-subjects-ages-12-35-with-recently-di-081a430772a57e08Pharma Surgeen2026-07-02T00:00:00.000ZNCT06783309: CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)https://www.pharmaradar360.com/article/nct06692179-an-open-label-pilot-clinical-trial-to-test-the-safety-and-feasibilit-bcf9467b56f117f6Pharma Surgeen2026-07-02T00:00:00.000ZNCT06692179: An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resectionhttps://www.pharmaradar360.com/article/nct06489535-retention-and-re-engagement-in-treatment-for-addiction-following-ser-24bad896a7c0300bPharma Surgeen2026-07-02T00:00:00.000ZNCT06489535: Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)https://www.pharmaradar360.com/article/nct06464185-a-prospective-clinical-study-of-cd3-cd20-bisspecific-antibody-based-c2ce225dca1cee50Pharma Surgeen2026-07-02T00:00:00.000ZNCT06464185: A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphomahttps://www.pharmaradar360.com/article/nct06323837-mirtazapine-for-the-treatment-of-methamphetamine-use-in-opioid-use-d-d7559345afdf13f4Pharma Surgeen2026-07-02T00:00:00.000ZNCT06323837: Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatmenthttps://www.pharmaradar360.com/article/nct06170788-sacituzumab-tirumotecan-mk-2870-in-combination-with-pembrolizumab-ve-a9bc493859175614Pharma Surgeen2026-07-02T00:00:00.000ZNCT06170788: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)https://www.pharmaradar360.com/article/nct06101277-locally-ablative-therapy-for-oligo-progressive-gastrointestinal-mali-b8a90af91948624fPharma Surgeen2026-07-02T00:00:00.000ZNCT06101277: Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)https://www.pharmaradar360.com/article/nct06066723-19f-mri-in-healthy-children-and-children-with-mild-cystic-fibrosis-l-3023d32c788b761ePharma Surgeen2026-07-02T00:00:00.000ZNCT06066723: 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Diseasehttps://www.pharmaradar360.com/article/nct06052254-dexmedetomidine-transdermal-systems-dmts-treatment-for-agitation-ass-bbbf3eea8e03927fPharma Surgeen2026-07-02T00:00:00.000ZNCT06052254: Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Typehttps://www.pharmaradar360.com/article/nct05990075-an-ehealth-intervention-to-increase-depression-treatment-initiation-42b7aba985d8b055Pharma Surgeen2026-07-02T00:00:00.000ZNCT05990075: An eHealth Intervention to Increase Depression Treatment Initiation and Adherence Among Veterans Referred for Mental Health Serviceshttps://www.pharmaradar360.com/article/nct05979311-a-study-to-evaluate-the-efficacy-safety-and-tolerability-of-using-an-17b03376980d93baPharma Surgeen2026-07-02T00:00:00.000ZNCT05979311: A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapyhttps://www.pharmaradar360.com/article/nct05797870-selective-internal-radiation-therapy-and-188re-sss-lipiodol-treatmen-6fc1a8b171f437cePharma Surgeen2026-07-02T00:00:00.000ZNCT05797870: Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)https://www.pharmaradar360.com/article/nct05504720-evaluating-pembrolizumab-trastuzumab-and-flot-as-perioperative-treat-83e570064019ab52Pharma Surgeen2026-07-02T00:00:00.000ZNCT05504720: Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinomahttps://www.pharmaradar360.com/article/nct04864158-prosthesis-versus-active-exercise-program-in-patients-with-rotator-c-7170f4ff0fe3be88Pharma Surgeen2026-07-02T00:00:00.000ZNCT04864158: Prosthesis Versus Active Exercise Program in Patients With Rotator Cuff Arthropathyhttps://www.pharmaradar360.com/article/nct04821895-oncogenetic-panel-and-integrated-clinical-data-registry-study-for-wi-aace604c22eb0af0Pharma Surgeen2026-07-02T00:00:00.000ZNCT04821895: Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patientshttps://www.pharmaradar360.com/article/nct04603001-study-of-oral-ly3410738-in-patients-with-advanced-hematologic-malign-b2a66532860664dePharma Surgeen2026-07-02T00:00:00.000ZNCT04603001: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutationshttps://www.pharmaradar360.com/article/nct04427761-a-study-of-the-life-changes-experienced-by-patients-with-pancreatic-7b65b894b9e43cd7Pharma Surgeen2026-07-02T00:00:00.000ZNCT04427761: A Study of the Life Changes Experienced by Patients With Pancreatic Cancerhttps://www.pharmaradar360.com/article/nct04264897-antecedent-metabolic-health-and-metformin-aging-study-7ae167792660eb7bPharma Surgeen2026-07-02T00:00:00.000ZNCT04264897: Antecedent Metabolic Health and Metformin Aging Studyhttps://www.pharmaradar360.com/article/nct03603002-pathologic-and-immunologic-response-after-ablative-radiation-in-lung-d89db550d6cb3928Pharma Surgeen2026-07-02T00:00:00.000ZNCT03603002: Pathologic and Immunologic Response After Ablative Radiation in Lung Cancerhttps://www.pharmaradar360.com/article/nct03391973-pembrolizumab-in-patients-with-poor-prognosis-carcinoma-of-unknown-p-32af9f10e3390821Pharma Surgeen2026-07-02T00:00:00.000ZNCT03391973: Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)https://www.pharmaradar360.com/article/nct03150693-inotuzumab-ozogamicin-and-frontline-chemotherapy-in-treating-young-a-a8ae17c50c522207Pharma Surgeen2026-07-02T00:00:00.000ZNCT03150693: Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/nct02471170-protocol-to-permit-the-acquisition-of-circulating-tumor-material-in-eceed22ef9c45dd9Pharma Surgeen2026-07-02T00:00:00.000ZNCT02471170: Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseaseshttps://www.pharmaradar360.com/article/nct02225600-the-effect-of-oxytocin-administration-on-interpersonal-cooperation-i-891fd17800e0ccacPharma Surgeen2026-07-02T00:00:00.000ZNCT02225600: The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adultshttps://www.pharmaradar360.com/article/nct01778569-the-psoriasis-atherosclerosis-and-cardiometabolic-disease-initiative-90e31467bf83de5dPharma Surgeen2026-07-02T00:00:00.000ZNCT01778569: The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)https://www.pharmaradar360.com/article/nct01325961-medico-economic-evaluation-of-imrt-by-hi-art-rapidarc-vmat-therapy-i-57d1a59ecf1d2f4cPharma Surgeen2026-07-02T00:00:00.000ZNCT01325961: Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancershttps://www.pharmaradar360.com/article/nct01109394-comprehensive-omics-analysis-of-pediatric-and-adult-solid-tumors-and-2ba794ed1494f44ePharma Surgeen2026-07-02T00:00:00.000ZNCT01109394: Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studieshttps://www.pharmaradar360.com/article/nct00001373-familial-mediterranean-fever-and-related-disorders-genetics-and-dise-4b3e1fa258acfbd7Pharma Surgeen2026-07-02T00:00:00.000ZNCT00001373: Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristicshttps://www.pharmaradar360.com/article/world-pharmaceutical-grade-amino-acid-global-market-analysis-forecast-size-trend-2f3e4671f32ef131Pharma Surgeen2026-07-01T23:56:20.000ZWorld Pharmaceutical Grade Amino Acid Global - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/aob-pharma-taps-biorasi-to-execute-phase-2b-acne-trial-company-maintains-phase-3-4ef23e8c678de3e7Pharma Surgeen2026-07-01T22:27:22.000ZAOB Pharma Taps Biorasi to Execute Phase 2b Acne Trial; Company Maintains Phase 3 AD Trial Timelinehttps://www.pharmaradar360.com/article/draft-for-comments-guidelines-on-the-classification-of-deficiencies-observed-dur-09cb62c77aab8305Pharma Surgeen2026-07-01T21:25:02.000ZDraft for Comments || Guidelines on the Classification of Deficiencies Observed During Inspection of Drug Distributors, Drugstores, Hospital Pharmacies and Retail Outlet for Non-Prescription Drugs (RONPD)https://www.pharmaradar360.com/article/jetema-signs-zydus-deal-to-bring-glp-1-biosimilar-to-south-korea-chosunbiz-26a1eccf4f5066edPharma Surgeen2026-07-01T21:01:00.000ZJetema signs Zydus deal to bring GLP-1 biosimilar to South Korea - CHOSUNBIZhttps://www.pharmaradar360.com/article/kcmc-drives-korea-to-build-cmc-muscle-cut-china-reliance-win-drug-approvals-chos-49f202d6d6d33fadPharma Surgeen2026-07-01T21:01:00.000ZKCMC drives Korea to build CMC muscle, cut China reliance, win drug approvals - CHOSUNBIZhttps://www.pharmaradar360.com/article/rentschler-biopharma-hires-swiss-biotech-executive-as-next-ceo-cd60b412a92f5be1Pharma Surgeen2026-07-01T20:56:24.000ZRentschler BioPharma hires Swiss biotech executive as next CEOhttps://www.pharmaradar360.com/article/magnum-brand-products-may-be-harmful-due-to-hidden-drug-ingredients-64f5fc12343ed8d8Pharma Surgeen2026-07-01T20:53:12.000ZMAGNUM Brand products may be harmful due to hidden drug ingredientshttps://www.pharmaradar360.com/article/wall-street-thinks-this-high-flying-biotech-stock-can-soar-another-57-b8fe570097cabfbbPharma Surgeen2026-07-01T20:45:00.000ZWall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%https://www.pharmaradar360.com/article/can-ozempic-cause-joint-and-muscle-pain-f9f7e2e1cf0fa136Pharma Surgeen2026-07-01T20:29:01.000ZCan Ozempic Cause Joint and Muscle Pain?https://www.pharmaradar360.com/article/controversial-drug-at-center-of-multibillion-dollar-amgen-deal-faces-more-questi-99434b8ba32b304cPharma Surgeen2026-07-01T20:24:00.000ZControversial drug at center of multibillion-dollar Amgen deal faces more questions after paper retractedhttps://www.pharmaradar360.com/article/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-7a0a5d3dced52211Pharma Surgeen2026-07-01T20:15:34.000ZLSD therapy biotech Definium fends off trade-secret lawsuithttps://www.pharmaradar360.com/article/hhs-fda-commend-dea-action-against-dangerous-enhanced-7-oh-products-235d1143be6151cbPharma Surgeen2026-07-01T19:53:19.000ZHHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Productshttps://www.pharmaradar360.com/article/the-medicare-glp-1-bridge-pharmexec-0de7b67fcdffacd9Pharma Surgeen2026-07-01T19:52:53.000ZThe Medicare GLP-1 Bridge | PharmExechttps://www.pharmaradar360.com/article/what-do-moonlake-s-latest-week-40-hs-results-really-mean-for-investors-9f702ce2a4a5c8ffPharma Surgeen2026-07-01T19:15:53.000ZWhat Do MoonLake's Latest Week 40 HS Results Really Mean for Investorshttps://www.pharmaradar360.com/article/biotech-s-resurgence-a-video-recap-of-bio-2026-5fbc3c3c6eb6df24Pharma Surgeen2026-07-01T18:44:03.000ZBiotech's Resurgence: A Video Recap of BIO 2026https://www.pharmaradar360.com/article/nueva-convocatoria-de-la-revista-cientifica-anmat-98174685cba8e209Pharma Surgeen2026-07-01T16:46:15.000ZNueva convocatoria de la Revista Científica ANMAThttps://www.pharmaradar360.com/article/june-s-top-etfs-biotech-china-semiconductors-surge-54047aa893f55ba8Pharma Surgeen2026-07-01T16:35:18.000ZJune's Top ETFs: Biotech & China Semiconductors Surgehttps://www.pharmaradar360.com/article/14-new-weight-loss-drugs-8f97f67645d6c678Pharma Surgeen2026-07-01T16:30:21.000Z14 New Weight Loss Drugshttps://www.pharmaradar360.com/article/the-acta-just-got-an-upgrade-d847f71c5d67e575Pharma Surgeen2026-07-01T16:18:24.000ZThe ACTA Just Got an Upgradehttps://www.pharmaradar360.com/article/medicare-will-spend-more-than-13-billion-on-the-medicare-advantage-quality-bonus-2a82a6a0bff86a8dPharma Surgeen2026-07-01T16:15:00.000ZMedicare Will Spend More Than $13 Billion on the Medicare Advantage Quality Bonus Program in 2026https://www.pharmaradar360.com/article/decoding-medicare-advantage-coding-intensity-74892946070d5963Pharma Surgeen2026-07-01T16:15:00.000ZDecoding Medicare Advantage Coding Intensityhttps://www.pharmaradar360.com/article/carolina-s-school-of-data-and-information-sciences-launches-3bcc4095492be6abPharma Surgeen2026-07-01T16:10:40.000ZCarolina’s School of Data and Information Sciences launcheshttps://www.pharmaradar360.com/article/collaboration-is-key-for-carolina-s-newest-school-d3925202e1effa31Pharma Surgeen2026-07-01T16:09:09.000ZCollaboration is key for Carolina’s newest schoolhttps://www.pharmaradar360.com/article/10-million-gift-launches-statewide-effort-to-expand-access-to-care-in-rural-alab-eff6204cc1984890Pharma Surgeen2026-07-01T16:07:53.000Z$10 million gift launches statewide effort to expand access to care in rural Alabamahttps://www.pharmaradar360.com/article/skin-cancer-risk-in-congenital-ichthyoses-how-all-of-us-data-supports-real-world-e7372772e9715505Pharma Surgeen2026-07-01T16:07:32.000ZSkin Cancer Risk in Congenital Ichthyoses: How All of Us Data Supports Real-World Rare Disease Researchhttps://www.pharmaradar360.com/article/fda-s-sunscreen-rules-leave-americans-exposed-8eac80f555711df3Pharma Surgeen2026-07-01T16:02:25.000ZFDA’s sunscreen rules leave Americans exposedhttps://www.pharmaradar360.com/article/oxford-researchers-become-embo-members-76884d7309bb0d70Pharma Surgeen2026-07-01T16:02:00.000ZOxford researchers become EMBO membershttps://www.pharmaradar360.com/article/fda-scientists-warn-against-expanded-peptide-access-as-kennedy-reshapes-advisory-b66242723092caa6Pharma Surgeen2026-07-01T16:01:37.000ZFDA Scientists Warn Against Expanded Peptide Access As Kennedy Reshapes Advisory Panelhttps://www.pharmaradar360.com/article/jacob-smith-defies-early-prognosis-following-life-threatening-accident-664224178bee1dc0Pharma Surgeen2026-07-01T15:59:52.000ZJacob Smith defies early prognosis following life-threatening accidenthttps://www.pharmaradar360.com/article/medicare-s-glp-1-bridge-and-what-s-next-for-biotech-lly-nyse-4470e3b9b275cd47Pharma Surgeen2026-07-01T15:55:01.000ZMedicare's GLP-1 Bridge and what's next for biotech (LLY:NYSE)https://www.pharmaradar360.com/article/safe-use-of-electronic-devices-on-planes-3e53bd1d35dde82cPharma Surgeen2026-07-01T15:52:00.000ZSafe Use of Electronic Devices on Planeshttps://www.pharmaradar360.com/article/reliably-detecting-and-clearly-explaining-deepfake-images-dab264151fdd5c86Pharma Surgeen2026-07-01T15:52:00.000ZReliably Detecting and Clearly Explaining Deepfake Imageshttps://www.pharmaradar360.com/article/adressing-the-shortage-of-skilled-workers-with-lars-03b8c55e3a4c38adPharma Surgeen2026-07-01T15:52:00.000ZAdressing the Shortage of Skilled Workers With LARShttps://www.pharmaradar360.com/article/what-to-know-about-male-infertility-from-a-uab-urologist-9cc2608f34495905Pharma Surgeen2026-07-01T15:51:18.000ZWhat to know about male infertility from a UAB urologisthttps://www.pharmaradar360.com/article/teva-launches-hydrogen-truck-for-pharmaceutical-logistics-29d0fb0521d3abfdPharma Surgeen2026-07-01T15:50:00.000ZTeva Launches Hydrogen Truck for Pharmaceutical Logisticshttps://www.pharmaradar360.com/article/fda-recalls-and-warnings-foreign-substance-found-in-millions-of-steroid-eye-drop-3d4bb5dbe80252bfPharma Surgeen2026-07-01T15:38:09.000ZFDA Recalls and Warnings: Foreign Substance Found in Millions of Steroid Eye Drops, Seizure Drug Mix-Up & Morehttps://www.pharmaradar360.com/article/extreme-heat-is-rising-and-so-is-the-risk-to-your-heart-72e193ae4bf3db81Pharma Surgeen2026-07-01T15:30:00.000ZExtreme heat is rising — and so is the risk to your hearthttps://www.pharmaradar360.com/article/quantumcell-commits-2-2bn-on-alzecure-s-alzheimer-s-platform-344766e0011da79ePharma Surgeen2026-07-01T15:27:52.000ZQuantumCell commits $2.2bn on AlzeCure’s Alzheimer’s platformhttps://www.pharmaradar360.com/article/how-amendment-intelligence-helps-reduce-avoidable-protocol-revisions-c9a94cbc3f8e1244Pharma Surgeen2026-07-01T15:27:20.000ZHow Amendment Intelligence Helps Reduce Avoidable Protocol Revisionshttps://www.pharmaradar360.com/article/guidance-mhra-innovation-office-guidance-and-support-e3617b6abf32ab4ePharma Surgeen2026-07-01T15:26:45.000ZGuidance: MHRA Innovation Office: guidance and supporthttps://www.pharmaradar360.com/article/pfas-free-coatings-for-mdi-canisters-what-to-look-for-92f6f285972821e8Pharma Surgeen2026-07-01T15:22:53.000ZPFAS-free coatings for MDI canisters: What to look forhttps://www.pharmaradar360.com/article/bristol-myers-squibb-hires-lobbyist-on-drug-pricing-6fa0b056f7881fbePharma Surgeen2026-07-01T15:22:20.000ZBristol-Myers Squibb Hires Lobbyist on Drug Pricinghttps://www.pharmaradar360.com/article/postpartum-reintegration-an-uncomfortable-silence-pharmacy-can-no-longer-afford-8058a5c7f3fc1ebePharma Surgeen2026-07-01T15:15:54.000ZPostpartum reintegration: an uncomfortable silence pharmacy can no longer affordhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-welgene-biotech-co-ltd-tpex-6661-ba5b87640fd8ef80Pharma Surgeen2026-07-01T15:12:37.000ZPrice to earnings forward of Welgene Biotech Co., Ltd. – TPEX:6661https://www.pharmaradar360.com/article/devolved-governments-seen-to-favour-some-regions-e49247e1178d3a46Pharma Surgeen2026-07-01T14:59:25.000ZDevolved governments seen to favour some regionshttps://www.pharmaradar360.com/article/biophorum-unites-20-organizations-to-modernize-small-molecule-production-e2e4918eaded20e5Pharma Surgeen2026-07-01T14:53:53.000ZBioPhorum Unites 20 Organizations to Modernize Small Molecule Production